Phase II Study of a Combination of Irinotecan and Cisplatin Against Metastatic Gastric Cancer
作者： Narikazu Boku , Atsushi Ohtsu , Yasuhiro Shimada , Kuniaki Shirao , Shigeki Seki
DOI: 10.1200/JCO.1999.17.1.319
关键词:
摘要: PURPOSE: A phase II study of a combination chemotherapy regimen cisplatin (CDDP) and irinotecan (CPT-11) was conducted to assess its efficacy feasibility in patients with metastatic gastric cancer. PATIENTS AND METHODS: Eligibility criteria included the following: (1) histologically proven cancer measurable lesions, (2) performance status 2 or less, (3) age 75 years younger, (4) one no prior regimens, (5) adequate bone marrow, liver, renal, cardiac functions, (6) written informed consent. The treatment consisted CPT-11 (70 mg/m2) on day 1 15 CDDP (80 1, repeated every 4 weeks. RESULTS: Forty-four were entered onto study. overall response rate 48% (21 44 patients, 95% confidence interval [CI], 33% 63%) complete remission (2%). who had not received 59% (17 29 CI, 39% 77%). median survival time...
sci-hub.se 参考文章(26)
N Masuda, , M Fukuoka, A Fujita, Y Kurita, S Tsuchiya, K Nagao, S Negoro, H Nishikawa, N Katakami, K Nakagawa, H Niitani, A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group. British Journal of Cancer. ,vol. 78, pp. 251- 256 ,(1998) , 10.1038/BJC.1998.473
Barbara G. Lubejko, Louise B. Grochow, David S. Ettinger, Susan E. Sartorius, Ross C. Donehower, Eric K. Rowinsky, Michael K. Rock, Tian-Ling Chen, Phase I and Pharmacological Study of the Novel Topoisomerase I Inhibitor 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) Administered as a Ninety-Minute Infusion Every 3 Weeks Cancer Research. ,vol. 54, pp. 427- 436 ,(1994)
Teruo Yokokura, Tadashi Miyasaka, Hiroyasu Baba, Kazuo Nitta, Siego Sawada, Masahiko Mutai, Mieko Takeuchi, Tomiko Tanaka, Nobuaki Uehara, Takehiko Kunimoto, Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Research. ,vol. 47, pp. 5944- 5947 ,(1987)
Fumihiko Kanzawa, Nagahiro Saijo, Hitoshi Arioka, Tomoyuki Ishida, Hayato Ogasawara, Mikio Oka, Kazuto Nishio, Krzysztof Bojanowski, Minoru Fukuda, Synergism between Cisplatin and Topoisomerase I Inhibitors, NB-506 and SN-38, in Human Small Cell Lung Cancer Cells Cancer Research. ,vol. 56, pp. 789- 793 ,(1996)
A Gouyette, G G Chabot, M de Forni, A Mathieu-Boué, J M Extra, R Bugat, M E Marty, I Madelaine, S Culine, Phase I and Pharmacokinetic Study of the Camptothecin Derivative Irinotecan, Administered on a Weekly Schedule in Cancer Patients Cancer Research. ,vol. 54, pp. 4347- 4354 ,(1994)
D Abigerges, G G Chabot, J P Armand, P Hérait, A Gouyette, D Gandia, Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. Journal of Clinical Oncology. ,vol. 13, pp. 210- 221 ,(1995) , 10.1200/JCO.1995.13.1.210
Stanley Kirschenbaum, Govindar Manikumar, Robert Silber, Monroe E. Wall, Allan W. Nicholas, Milan Potmesil, Yaw-Huei Hsiang, Leroy F. Liu, Mansukh C. Wani, DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues Cancer Research. ,vol. 49, pp. 4385- 4389 ,(1989)
P Preusser, H Wilke, W Achterrath, U Fink, L Lenaz, A Heinicke, J Meyer, H J Meyer, H Buente, Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. Journal of Clinical Oncology. ,vol. 7, pp. 1310- 1317 ,(1989) , 10.1200/JCO.1989.7.9.1310
K Shirao, Y Shimada, H Kondo, D Saito, T Yamao, H Ono, T Yokoyama, H Fukuda, M Oka, Y Watanabe, A Ohtsu, N Boku, T Fujii, Y Oda, K Muro, S Yoshida, Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. Journal of Clinical Oncology. ,vol. 15, pp. 921- 927 ,(1997) , 10.1200/JCO.1997.15.3.921
C G Moertel, J Rubin, M J O'Connell, A J Schutt, H S Wieand, A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. Journal of Clinical Oncology. ,vol. 4, pp. 1053- 1057 ,(1986) , 10.1200/JCO.1986.4.7.1053